Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks

This study has been completed.
Santa Clara Valley Medical Center
Information provided by (Responsible Party):
Kate Ayers Shaw, Stanford University Identifier:
First received: May 30, 2012
Last updated: April 4, 2014
Last verified: April 2014

A common practice for preparation for surgical abortion after 19 weeks gestation is the placement of multiple sets of osmostic dilators 1-2 days prior to the procedure. The investigators aim to study the addition of mifepristone as an adjunct to cervical dilation prior to abortion between 19-24 weeks gestation, and its potential to minimize the number of painful procedures and time in clinic (or away from work/home) that multiple sets of dilators can require. The investigators hypothesize that one set of dilators with mifepristone will result in similar procedure times and decreased "total" time as two sets of dilators.

Condition Intervention
Abortion, Induced
Drug: Mifepristone
Other: Hygroscopic cervical dilators
Drug: Misoprostol
Drug: Intra-amniotic digoxin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Procedure Time [ Time Frame: Intraoperative Time ] [ Designated as safety issue: No ]
    Measured as time from speculum insertion to removal

Secondary Outcome Measures:
  • Total Procedure Time [ Time Frame: Measured at clinic visits and on OR day, over a 3 day period ] [ Designated as safety issue: No ]
    All time required by patient (time in clinic for cervical preparation procedures)

  • Maximum cervical dilation [ Time Frame: Measured intra-operatively ] [ Designated as safety issue: No ]
    Measured by estimate with bimanual exam and passage of largest dilator immediately prior to procedure.

  • Adverse Events [ Time Frame: Intraoperatively and 2 weeks post operatively ] [ Designated as safety issue: Yes ]
    estimated blood loss, uterine injury, infection, retained products of conception

  • Ease of Procedure by Blinded Surgeon [ Time Frame: Measured Immediately after procedure ] [ Designated as safety issue: No ]
    Using Visual Analogue Scale

  • Pain perceived by patient [ Time Frame: Measured during dilator placement ] [ Designated as safety issue: No ]
    Using Visual Analogue Scale- baseline, after speculum placement, after paracervical block, after dilator placement

  • Overall patient experience [ Time Frame: Measured post operatively (at least 30 minutes) prior to discharge ] [ Designated as safety issue: No ]
    Using visual analogue scale

Estimated Enrollment: 50
Study Start Date: May 2012
Study Completion Date: July 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Two sets of dilators
Two sets of osmotic dilators inserted 1 and 2 days pre-op
Other: Hygroscopic cervical dilators
Dilapan-S osmostic cervical dilators inserted through the internal os
Other Name: Dilapan-S
Drug: Misoprostol
400mcg buccal misoprostol 90 minutes pre-op
Drug: Intra-amniotic digoxin
1mg digoxin administered intra-amniotically ~24 hours pre-op
Experimental: Mifepristone plus one set of dilators
One set of dilators plus mifepristone
Drug: Mifepristone
200mg Mifepristone orally
Other Name: Danco, Mifeprex
Other: Hygroscopic cervical dilators
Dilapan-S osmostic cervical dilators inserted through the internal os
Other Name: Dilapan-S
Drug: Misoprostol
400mcg buccal misoprostol 90 minutes pre-op
Drug: Intra-amniotic digoxin
1mg digoxin administered intra-amniotically ~24 hours pre-op


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >18 years old
  • Viable, Singleton pregnancy
  • Voluntarily seeking abortion between 19 and 24wks gestation
  • Able to give informed consent and comply with study protocol
  • Fluent in English or Spanish

Exclusion Criteria:

  • Allergy to misoprostol or mifepristone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01615731

United States, California
Santa Clara Valley Medical Center
San Jose, California, United States, 95128
Stanford University Medical Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Santa Clara Valley Medical Center
Principal Investigator: Kate A Shaw, MD Stanford University
  More Information

No publications provided

Responsible Party: Kate Ayers Shaw, Clinical Instructor, Clinical Fellow, Stanford University Identifier: NCT01615731     History of Changes
Other Study ID Numbers: SU-05302012-10088
Study First Received: May 30, 2012
Last Updated: April 4, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Induced Abortion
Dilation and Evacuation
Cervical preparation
Osmotic dilators

Additional relevant MeSH terms:
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents, Steroidal
Anti-Ulcer Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic
Gastrointestinal Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 23, 2014